⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22682851 | 1.00 | — | — | |
| SCHEMBL1065644 | 0.91 | — | — | |
| SCHEMBL1408600 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL18145177 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL3986300 | 0.73 | — | — | |
| SCHEMBL1047645 | 0.73 | — | — | |
| SCHEMBL34914 | 0.72 | ALDH1A1 (0.30) | — | |
| SCHEMBL375711 | 0.68 | — | — | |
| SCHEMBL23451831 | 0.67 | — | — | |
| SCHEMBL22037 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503889-A1 | INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | Board Of Regents, The University Of Texas System (US) | 2019-07-03 | — | — | EP | claimed |
| WO-2018044808-A1 | INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-08 | — | — | WO | claimed |
| US-20180057507-A1 | INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-03-01 | — | — | US | claimed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | claimed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | claimed |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-12-12 | — | — | US | claimed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | claimed |
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| EP-1586565-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | Pharmacia Corporation (US) | 2005-10-19 | — | — | EP | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000069832-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000069826-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0421752-A2 | Substituted acrylamido-penicillanic acid derivatives | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | claimed |
| EP-0247431-A1 | Substituted 6-hydroxymethylcarbapenem antibiotics, process for their preparation and their use | BAYER AG (DE) | 1987-12-02 | — | — | EP | claimed |
| US-4477460-A | Topical treatment of ocular hypertension | SYNTEX (U.S.A.) INC. (US) | 1984-10-16 | — | — | US | claimed |